AI Diagnostics: The End of the High-Cost Imaging Era
View original at globenewswire.comAI Diagnostics: The End of the High-Cost Imaging Era VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
The SAPIEN M3 system's ability to provide fully percutaneous mitral valve replacement that safely delivers near elimination of significant mitral regurgitation is a game-changer for patients
80% confidenceDevice-as-a-Service subscription model will shorten sales cycles and build recurring revenue streams making technology accessible to more healthcare facilities without large upfront capital investments
80% confidenceThe AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034
80% confidencePartnership with Summit Sciences will enable delivery of more compelling value propositions to customers and ensure solutions make strong economic sense for healthcare providers
80% confidenceAetna's coverage decision is a pivotal step in expanding access to AI-driven plaque quantification technology, with coverage now available for the majority of insured lives across the United States
80% confidenceStroke patients require quick treatment access, but in-hospital stroke patients often experience hours of delay, making the Ceribell System's potential for accurate and timely LVO stroke detection critically important
80% confidenceValue-based care is reaching a digital tipping point in 2026 where connected platforms are no longer a 'nice-to-have' but a survival requirement for healthcare providers
80% confidence2025 marked another outstanding year for AtriCure with strong growth and transformative innovation, including new product launches, LeAAPS trial enrollment completion, and significant business leverage
80% confidence